Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874) Cyclically Adjusted FCF per Share: HK$1.01 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00874 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd HKSE:00874
88 GF Score
Price HK$13.31
GF Value HK$19.01
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Cyclically Adjusted FCF per Share?

Guangzhou Baiyunshan Pharmaceutical Holdings Co HKSE:00874 -0.89% 88 Cyclically Adjusted FCF per Share is HK$1.01 as of Jun. 2026. GuruFocus rates HKSE:00874 with a GF Score™ of 88/100 and a GF Value™ of HK$19.01 (Significantly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's adjusted free cash flow per share for the three months ended in Jun. 2026 was HK$1.175. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is HK$1.01 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Guangzhou Baiyunshan Pharmaceutical Holdings Co's average Cyclically Adjusted FCF Growth Rate was -4.00% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -2.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 7.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 16.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Guangzhou Baiyunshan Pharmaceutical Holdings Co was 59.70% per year. The lowest was -2.50% per year. And the median was 18.20% per year.

As of today (2026-09-12), Guangzhou Baiyunshan Pharmaceutical Holdings Co's current stock price is HK$13.31. Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was HK$1.01. Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted Price-to-FCF of today is 13.18.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Guangzhou Baiyunshan Pharmaceutical Holdings Co was 59.49. The lowest was 13.80. And the median was 23.08.


Guangzhou Baiyunshan Pharmaceutical Holdings Co  (HKSE:00874) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=13.31/1.01
=13.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Guangzhou Baiyunshan Pharmaceutical Holdings Co was 59.49. The lowest was 13.80. And the median was 23.08.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Guangzhou Baiyunshan Pharmaceutical Holdings Co Cyclically Adjusted FCF per Share Related Terms


Guangzhou Baiyunshan Pharmaceutical Holdings Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Cyclically Adjusted FCF per Share Chart

Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.95 1.35 1.37 1.16 1.12

Guangzhou Baiyunshan Pharmaceutical Holdings Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 1.10 1.12 1.03 1.01

HKSE:00874 vs MCK, COR, CAH: Cyclically Adjusted FCF per Share Comparison

For the Medical Distribution subindustry, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangzhou Baiyunshan Pharmaceutical Holdings Co Cyclically Adjusted Price-to-FCF vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted Price-to-FCF falls into.


HKSE:00874
88GF Score
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd HKSE:00874
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Baiyunshan Pharmaceutical Holdings Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Guangzhou Baiyunshan Pharmaceutical Holdings Co's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.175/116.0564*116.0564
=1.175

Current CPI (Jun. 2026) = 116.0564.

Guangzhou Baiyunshan Pharmaceutical Holdings Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.585 102.400 0.663
201612 0.003 102.600 0.003
201703 0.227 103.200 0.255
201706 0.337 103.100 0.379
201709 0.646 104.100 0.720
201712 -0.042 104.500 -0.047
201803 0.577 105.300 0.636
201806 0.247 104.900 0.273
201809 1.441 106.600 1.569
201812 1.121 106.500 1.222
201903 -2.143 107.700 -2.309
201906 0.167 107.700 0.180
201909 1.177 109.800 1.244
201912 2.507 111.200 2.616
202003 -2.422 112.300 -2.503
202006 0.565 110.400 0.594
202009 1.811 111.700 1.882
202012 -0.112 111.500 -0.117
202103 1.068 112.662 1.100
202106 0.183 111.769 0.190
202109 2.456 112.215 2.540
202112 -0.449 113.108 -0.461
202203 0.488 114.335 0.495
202206 0.373 114.558 0.378
202209 0.853 115.339 0.858
202212 2.209 115.116 2.227
202303 -2.153 115.116 -2.171
202306 1.059 114.558 1.073
202309 0.821 115.339 0.826
202312 1.838 114.781 1.858
202403 -2.309 115.227 -2.326
202406 0.567 114.781 0.573
202409 0.703 115.785 0.705
202412 2.546 114.893 2.572
202503 -2.719 115.116 -2.741
202506 0.154 114.907 0.156
202509 0.681 115.471 0.684
202512 0.957 115.832 0.959
202603 -1.706 116.303 -1.702
202606 1.175 116.056 1.175

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of HK$1.01 mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874) has a Cyclically Adjusted FCF per Share of HK$1.01 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted FCF per Share too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Cyclically Adjusted FCF per Share is HK$1.01. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted FCF per Share compare to MCK and COR?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Cyclically Adjusted FCF per Share of HK$1.01 can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Distribution company?
A good Cyclically Adjusted FCF per Share depends on the Medical Distribution industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Cyclically Adjusted FCF per Share is HK$1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$19.01, compared to a current price of HK$13.31 — trading 30% below its estimated fair value. The current Cyclically Adjusted FCF per Share is HK$1.01. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874), the current Cyclically Adjusted FCF per Share is HK$1.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874) Overvalued in 2026?

Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued. The current stock price of HK$13.31 is trading 30% below its estimated GF Value™ of HK$19.01. GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.

Key valuation signals for HKSE:00874:

  • Cyclically Adjusted FCF per Share: HK$1.01
  • GF Value™: HK$19.01 vs. price of HK$13.31 (30% below fair value)
  • GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the HKSE:00874 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Guangzhou Baiyunshan Pharmaceutical Holdings Co Business Description

Other Exchanges GU5:Germany600332:China
Address 45 Sha Mian North Street, Liwan District, Guangdong Province, Guangzhou, CHN, 510130
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
88GF Score

Get the complete analysis for HKSE:00874

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$13.31
Price
HK$19.01
GF Value